高级检索
当前位置: 首页 > 详情页

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 (Open Access)

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 自然指数

机构: [1]Department of Cardiology, Renmin Hospital, School of Basic Medical Science, Wuhan University, Wuhan, China [2]Institute of Model Animal, Wuhan University, Wuhan, China [3]Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China [4]Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China [5]Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19004, USA [6]Centre for Clinic Pharmacology, The William Harvey Research Institute, Queen Mary University of London, London, UK [7]Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan430072, China [8]Department of Neurology, Wuhan First Hospital/Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan 430072, China [9]Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, China [10]Department of General Surgery, Huanggang Central Hospital, Huanggang 438000, China [11]Wuhan Seventh Hospital, Wuhan 430072, China [12]Department of Stomatology, Xiantao First People’s Hospital, Xiantao 433000, China [13]Department of Neurology, The First People’s Hospital of Jingmen Affiliated to Hubei Minzu University, Jingmen 448000, China [14]Department of Hepatobiliary and Pancreatic Surgery, Suizhou Central Hospital Affiliated to Hubei Medical College, Suizhou 441300, China [15]The Ninth Hospital of Wuhan City, Wuhan 430072, China [16]Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’sHospital and Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, China [17]Department of Intensive Care Unit, Wuhan Third Hospital & Tongren Hospital of Wuhan University, Wuhan, China [18]The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi 445000, China [19]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Changjiang University, Jingzhou, China [20]Department of Hepatobiliary Surgery, Jingzhou Central Hospital, Jingzhou, China [21]Department of Hepatobiliary and Pancreatic Surgery, Xianning Central Hospital, Xianning, Hubei Province, China [22]Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China [23]Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, China [24]Department of Neonatology, Renmin Hospital of Wuhan University, Wuhan, China [25]Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada [26]NAFLD Research Center, Division of Gastroenterology and Epidemiology, University of California, San Diego, San Diego, CA, USA [27]Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,China [28]Departments of Anesthesiology, Physiology, and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine,University of California, Los Angeles, Los Angeles, CA, USA [29]Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha 410000, China [30]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine & Key Laboratory of Glucolipid MetabolicDisorder, Ministry of Education of China & Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM KeyLaboratory for Metabolic Diseases, Guangzhou 510006, China
出处:
ISSN:

关键词: ACEi/ARB COVID-19 mortality SARS-COV-2 statin

摘要:
Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression. Here, we performed a retrospective study on 13,981 patients with COVID-19 in Hubei Province, China, among which 1,219 received statins. Based on a mixed-effect Cox model after propensity score-matching, we found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with an adjusted hazard ratio of 0.58. The statin use-associated lower risk of mortality was also observed in the Cox time-varying model and marginal structural model analysis. These results give support for the completion of ongoing prospective studies and randomized controlled trials involving statin treatment for COVID-19, which are needed to further validate the utility of this class of drugs to combat the mortality of this pandemic. © 2020 Elsevier Inc.

基金:
语种:
高被引:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 生物
小类 | 1 区 细胞生物学 1 区 内分泌学与代谢
最新[2025]版:
大类 | 1 区 生物学
小类 | 1 区 细胞生物学 1 区 内分泌学与代谢
JCR分区:
出版当年[2018]版:
Q1 ENDOCRINOLOGY & METABOLISM Q1 CELL BIOLOGY
最新[2023]版:
Q1 CELL BIOLOGY Q1 ENDOCRINOLOGY & METABOLISM

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Cardiology, Renmin Hospital, School of Basic Medical Science, Wuhan University, Wuhan, China [2]Institute of Model Animal, Wuhan University, Wuhan, China [3]Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Cardiology, Renmin Hospital, School of Basic Medical Science, Wuhan University, Wuhan, China [2]Institute of Model Animal, Wuhan University, Wuhan, China [3]Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China [4]Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号